Renejix CDMO Partner for Small Molecule Oral Dosage Forms Renejix CDMO Partner for Small Molecule Oral Dosage Forms

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Psycheceutical.

    Client Virtual Booth

    PSYCHECEUTICAL

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Psycheceutical
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    515 E. Las Olas Blvd Suite 120 Fort Lauderdale, FL 33301
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://psycheceutical.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/psycheceutical/
    Twitter
    Twitter
    https://twitter.com/psycheceutical/

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating PTSD

    Details:

    NeuroDirect (ketamine) is a rapid-acting general anesthetic and NMDA receptor antagonist used for induction of anesthesia diagnostic and surgical procedures typically in combination with a muscle relaxant, for treating PTSD.


    Lead Product(s): Ketamine Hydrochloride

    Therapeutic Area: Psychiatry/Psychology Product Name: NeuroDirect

    Highest Development Status: PreclinicalProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 21, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD

    Details:

    Psycheceutical ​​enters into agreement with iNGENū to conduct ​human ​clinical trials of NeuroDirect™ ketamine topical to treat Post-traumatic stress disorder ​in Australia.


    Lead Product(s): Ketamine Hydrochloride

    Therapeutic Area: Psychiatry/Psychology Product Name: NeuroDirect™ Ketamine

    Highest Development Status: IND EnablingProduct Type: Small molecule

    Partner/Sponsor/Collaborator: iNGENū

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement February 15, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSD

    Details:

    Ketamine is a rapid-acting general anesthetic and NMDA receptor antagonist used for induction of anesthesia diagnostic and surgical procedures typically in combination with a muscle relaxant. It is being currently developed for PTSD.


    Lead Product(s): Ketamine Hydrochloride

    Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

    Highest Development Status: IND EnablingProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable February 02, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Psycheceutical Bioscience, Inc. Enters into Exclusive Option to Acquire Vici Health Sciences

    Details:

    Vici is an end-to-end pharmaceutical research and development company specializing in taking projects from pre-clinical research through the Phase 2 stage of FDA approval.


    Lead Product(s): Undisclosed

    Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

    Highest Development Status: PreclinicalProduct Type: Small molecule

    Recipient: Vici Health Sciences

    Deal Size: $10.5 million Upfront Cash: $10.5 million

    Deal Type: Acquisition August 16, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    farmak-a-s-m-2024-08-26

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search